Trastuzumab beyond progression in HER2-positive metastatic breast cancer

被引：1
|
作者：
Al-Naqqash, Manwar [1 ,2 ]
Jasim Al-Serarati, Waleed [3 ]
Farooq Kareem, Tara [4 ]
机构：
[1] Univ Baghdad, Dept Surg, Coll Med, Baghdad 10001, Iraq
[2] Minist Hlth Environm, Dept Radiat Oncol, Oncol Teaching Hosp, Baghdad Med City Complex, Baghdad, Iraq
[3] Minist Hlth & Environm, Dept Oncol, Baghdad Med City Complex, Baghdad, Iraq
[4] Minist Hlth & Environm, Oncol Teaching Hosp, Dept Diagnost Radiol, Baghdad Med City Complex, Baghdad, Iraq
来源：
BREAST JOURNAL | 2021年 / 27卷 / 03期
关键词：
breast cancer; HER2; neu; time to progression; trastuzumab;
D O I：
10.1111/tbj.14157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：297 / 299
页数：3
相关论文
共 50 条
  • [31] Trastuzumab as Single Agent Therapy for HER2-Positive Metastatic Breast Cancer
    Rastogi, Priya
    Davidson, Nancy E.
    ONKOLOGIE, 2010, 33 (8-9): : 420 - 421
  • [32] Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience
    Al-Shamsi, Humaid O.
    Fahmawi, Yazan
    Dahbour, Ibrahim
    Tabash, Aziz
    Rogers, Jane E.
    Mares, Jeannette Elizabeth
    Blum, Mariela A.
    Estrella, Jeannelyn
    Matamoros, Aurelio, Jr.
    Sagebiel, Tara
    Devine, Catherine E.
    Badgwell, Brian D.
    Lin, Quan D.
    Das, Prajnan
    Ajani, Jaffer A.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2016, 7 (04) : 499 - 505
  • [33] Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer
    Tina Nie
    Hannah A. Blair
    Targeted Oncology, 2023, 18 : 463 - 470
  • [34] Beyond trastuzumab: New treatment options for HER2-positive breast cancer
    Saini, Kamal S.
    Azim, Hatem A., Jr.
    Metzger-Filho, Otto
    Loi, Sherene
    Sotiriou, Christos
    de Azambuja, Evandro
    Piccart, Martine
    BREAST, 2011, 20 : S20 - S27
  • [35] Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer
    Paridaens, R., Sr.
    Wildiers, H.
    Dalenc, F.
    Rixe, O.
    Cadic, V.
    Pinel, M.
    Roche, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Biodistribution and pharmacokinetics of radiolabeled trastuzumab in HER2-positive metastatic breast cancer
    Hooge, MNLD
    Perik, PJ
    Gietema, JA
    Jager, PL
    Jonkman, S
    Kosterink, JGW
    Van Veldhuisen, DJJ
    Van der Graaf, WTA
    Sleijfer, DTH
    De Vries, EGE
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 210S - 210S
  • [37] Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
    Jeyakumar, Alwin
    Younis, Tallal
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6
  • [38] Very long response with trastuzumab for metastatic Her2-positive breast cancer
    Lai-Tiong, F.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (06) : 1002 - 1003
  • [39] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [40] Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer
    Morris, Shannon R.
    Carey, Lisa A.
    ONCOLOGY-NEW YORK, 2006, 20 (14): : 1763 - 1771
12345